Measurement of structure (disease) modification in osteoarthritis

Roy D Altman

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Osteoarthritis (OA) research is beginning to focus on developing structure (disease) modifying treatments that will stabilize or reverse morphological changes, thereby altering the underlying pathologic process. The ability of anti-arthritic agents to modify the course of disease has been investigated in a limited number of clinical trials. Agents studied in published clinical trials include glycosaminoglycan-peptide complex (GP-C), glycosaminoglycan polysulfate (GAGPS), diacerein, and glucosamine sulphate. These clinical trials have been difficult to interpret and compare because the patients studied are often inadequately characterized or are not comparable across studies. Studies also vary with respect to the outcome measures analyzed and the methodology applied to measurement and data analysis. Further, in general, the rate of radiographic progression of OA is slow and is not consistent across populations and patients with varying disease severity. In man, the radiograph has been the gold standard for evaluating treatments. Further longitudinal validation of the radiograph is needed. As techniques improve, variation in the system and the number of patients needed in studies are decreasing. It may be that the radiograph will not achieve the needed degree of validation and will be supplanted by magnetic resonance imaging as the surrogate marker of joint status.

Original languageEnglish (US)
JournalOsteoarthritis and Cartilage
Volume12
Issue numberSUPLL.
DOIs
StatePublished - 2004

Fingerprint

Osteoarthritis
diacetylrhein
A73025
Clinical Trials
Glucosamine
Pathologic Processes
Magnetic resonance
Glycosaminoglycans
Peptides
Arthritis
Joints
Biomarkers
Magnetic Resonance Imaging
Outcome Assessment (Health Care)
Imaging techniques
Therapeutics
Research
Population
Sulfates

Keywords

  • Criteria
  • Osteoarthritis
  • Structure-modifying drugs
  • X-ray progression

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Measurement of structure (disease) modification in osteoarthritis. / Altman, Roy D.

In: Osteoarthritis and Cartilage, Vol. 12, No. SUPLL., 2004.

Research output: Contribution to journalArticle

@article{58c296d6c03e4a0d88e47b7f719fbc0e,
title = "Measurement of structure (disease) modification in osteoarthritis",
abstract = "Osteoarthritis (OA) research is beginning to focus on developing structure (disease) modifying treatments that will stabilize or reverse morphological changes, thereby altering the underlying pathologic process. The ability of anti-arthritic agents to modify the course of disease has been investigated in a limited number of clinical trials. Agents studied in published clinical trials include glycosaminoglycan-peptide complex (GP-C), glycosaminoglycan polysulfate (GAGPS), diacerein, and glucosamine sulphate. These clinical trials have been difficult to interpret and compare because the patients studied are often inadequately characterized or are not comparable across studies. Studies also vary with respect to the outcome measures analyzed and the methodology applied to measurement and data analysis. Further, in general, the rate of radiographic progression of OA is slow and is not consistent across populations and patients with varying disease severity. In man, the radiograph has been the gold standard for evaluating treatments. Further longitudinal validation of the radiograph is needed. As techniques improve, variation in the system and the number of patients needed in studies are decreasing. It may be that the radiograph will not achieve the needed degree of validation and will be supplanted by magnetic resonance imaging as the surrogate marker of joint status.",
keywords = "Criteria, Osteoarthritis, Structure-modifying drugs, X-ray progression",
author = "Altman, {Roy D}",
year = "2004",
doi = "10.1016/j.joca.2003.09.011",
language = "English (US)",
volume = "12",
journal = "Osteoarthritis and Cartilage",
issn = "1063-4584",
publisher = "W.B. Saunders Ltd",
number = "SUPLL.",

}

TY - JOUR

T1 - Measurement of structure (disease) modification in osteoarthritis

AU - Altman, Roy D

PY - 2004

Y1 - 2004

N2 - Osteoarthritis (OA) research is beginning to focus on developing structure (disease) modifying treatments that will stabilize or reverse morphological changes, thereby altering the underlying pathologic process. The ability of anti-arthritic agents to modify the course of disease has been investigated in a limited number of clinical trials. Agents studied in published clinical trials include glycosaminoglycan-peptide complex (GP-C), glycosaminoglycan polysulfate (GAGPS), diacerein, and glucosamine sulphate. These clinical trials have been difficult to interpret and compare because the patients studied are often inadequately characterized or are not comparable across studies. Studies also vary with respect to the outcome measures analyzed and the methodology applied to measurement and data analysis. Further, in general, the rate of radiographic progression of OA is slow and is not consistent across populations and patients with varying disease severity. In man, the radiograph has been the gold standard for evaluating treatments. Further longitudinal validation of the radiograph is needed. As techniques improve, variation in the system and the number of patients needed in studies are decreasing. It may be that the radiograph will not achieve the needed degree of validation and will be supplanted by magnetic resonance imaging as the surrogate marker of joint status.

AB - Osteoarthritis (OA) research is beginning to focus on developing structure (disease) modifying treatments that will stabilize or reverse morphological changes, thereby altering the underlying pathologic process. The ability of anti-arthritic agents to modify the course of disease has been investigated in a limited number of clinical trials. Agents studied in published clinical trials include glycosaminoglycan-peptide complex (GP-C), glycosaminoglycan polysulfate (GAGPS), diacerein, and glucosamine sulphate. These clinical trials have been difficult to interpret and compare because the patients studied are often inadequately characterized or are not comparable across studies. Studies also vary with respect to the outcome measures analyzed and the methodology applied to measurement and data analysis. Further, in general, the rate of radiographic progression of OA is slow and is not consistent across populations and patients with varying disease severity. In man, the radiograph has been the gold standard for evaluating treatments. Further longitudinal validation of the radiograph is needed. As techniques improve, variation in the system and the number of patients needed in studies are decreasing. It may be that the radiograph will not achieve the needed degree of validation and will be supplanted by magnetic resonance imaging as the surrogate marker of joint status.

KW - Criteria

KW - Osteoarthritis

KW - Structure-modifying drugs

KW - X-ray progression

UR - http://www.scopus.com/inward/record.url?scp=3242732456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242732456&partnerID=8YFLogxK

U2 - 10.1016/j.joca.2003.09.011

DO - 10.1016/j.joca.2003.09.011

M3 - Article

C2 - 14698647

AN - SCOPUS:3242732456

VL - 12

JO - Osteoarthritis and Cartilage

JF - Osteoarthritis and Cartilage

SN - 1063-4584

IS - SUPLL.

ER -